Evidence map›Paper›PMID 31439149›Full record

ArticleAdvances in virus research2019

Hantavirus entry: Perspectives and recent advances.

Eva Mittler, Maria Eugenia Dieterle, Lara M Kleinfelter, Megan M Slough, Kartik Chandran, Rohit K Jangra

Abstract read
In one paragraph

Article in Advances in virus research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
28.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Generation and Characterization of the Human Anti-HTNV Antibody KJJ4.International journal of molecular sciences · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Effect ofMicroorganisms · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Hantavirus GnACS infectious diseases · 2025
    Article
  19. Article
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Eva MittlerDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.
Maria Eugenia DieterleDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.
Lara M KleinfelterDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.
Megan M SloughDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.
Kartik ChandranDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States. Electronic address: kartik.chandran@einstein.yu.edu.
Rohit K JangraDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States. Electronic address: rohit.jangra@einstein.yu.edu.
Albert Einstein College of Medicine · US

Funding

Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral ThreatsU19AI142777 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI CHANDRAN, KARTIK · 2019 to 2023
$21.9M
Dissecting the receptor-mediated infection mechanisms of hantavirusesR01AI132633 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CHANDRAN, KARTIK · 2017 to 2021
$3.2M
NIAID NIH HHS R01 AI132633NIAID NIH HHS U19 AI142777
6 · The paper itself

Abstract

Hantaviruses are important zoonotic pathogens of public health importance that are found on all continents except Antarctica and are associated with hemorrhagic fever with renal syndrome (HFRS) in the Old World and hantavirus pulmonary syndrome (HPS) in the New World. Despite the significant disease burden they cause, no FDA-approved specific therapeutics or vaccines exist against these lethal viruses. The lack of available interventions is largely due to an incomplete understanding of hantavirus pathogenesis and molecular mechanisms of virus replication, including cellular entry. Hantavirus Gn/Gc glycoproteins are the only viral proteins exposed on the surface of virions and are necessary and sufficient to orchestrate virus attachment and entry. In vitro studies have implicated integrins (β

Indexed as

Host-Pathogen InteractionsVirus InternalizationBiomedical ResearchOrthohantavirusProtein BindingReceptors, VirusViral Envelope ProteinsVirus AttachmentReceptors, VirusViral Envelope ProteinsBunyavirusHantavirusHantavirus pulmonary syndromeHemorrhagic fever with renal syndromeVaccinesViral entryViral glycoproteinsViral glycoprotein structureViral receptors

Identifiers

PMID31439149
PMCPMC6881143
OpenAlexW2964424807

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.